Tolerability is the ceiling, and the ceiling is personal
Roughly four to seven per cent of trial participants discontinued for adverse events, mostly gastrointestinal, mostly during escalation. That is the empirical size of the…
Side effects
Page 14 of 21 of this archive, newest first.
What the new Saudi Arabia guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
The interventions with trial support, and the much longer list without
We separate what is supported, what is reasonable, and what is folklore, and we do not pretend the boundaries are crisp.
What the new Ireland guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new Japan guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
South Korea pharmacy body issues counselling standards for dulaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
Constipation is the one that responds best to boring measures
Dietary measures are widely recommended, plausible on mechanism, and supported mainly by observational data and clinical experience.
The upper rungs, ranked by evidence
Where the curve flattens, what flattens with it, and what does not.
What the new Brazil guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What STEP 4 and SURMOUNT-4 actually established
A plateau at an intermediate dose and a plateau at the maximum dose look identical from the outside and mean different things.
Switzerland pharmacy body issues counselling standards for exenatide initiation
The evidence base is thin and the document says so, which is to its credit.
Turkey pharmacy body issues counselling standards for tirzepatide initiation
The evidence base is thin and the document says so, which is to its credit.
Discontinuation rates, read honestly
Roughly four to seven per cent of trial participants discontinued for adverse events, mostly gastrointestinal, mostly during escalation. That is the empirical size of the…
What the new Poland guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the trials counted as intolerance
We set out the questions that distinguish a symptom to manage from a dose to change.
What the new Spain guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
A supply gap is a pharmacological event
One omitted dose is a labelling question. Four omitted doses is a clinical one. The two are routinely conflated.
The label says four weeks. The clinic says whatever holds.
The published ladder exists because a protocol needed a single number. Practice has never followed it exactly, and the regulatory file never assumed it would.
What the new Germany guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Japan pharmacy body issues counselling standards for exenatide initiation
The evidence base is thin and the document says so, which is to its credit.